苯巴比妥联合苯二氮䓬类治疗酒精戒断综合征:一项回顾性分析
这项多中心回顾性队列研究比较了因酒精戒断综合征入院后接受苯巴比妥联合苯二氮䓬类治疗与单用苯二氮䓬类治疗的患者。联合组苯二氮䓬类剂量显著更高(660 mg vs 340 mg,p<0.0001),校正后戒断缓解时间显著缩短(141.65 h vs 165.72 h,p<0.0001),但机械通气(19.42% vs 0.96%,p<0.0001)、吸入性肺炎(22.33% vs 5.77%,p=0.0006)和住院时间(8天 vs 6天,p=0.0197)均增加。联合组中24小时内早期启用苯巴比妥与更低的苯二氮䓬类累积剂量(530 mg vs 887.50 mg,p=0.002)和更短住院时间(6天 vs 10天,p=0.0017)相关。作者认为对重度酒精戒断高危患者,早期启用苯巴比妥似乎获益最大。
要点
- 联合组苯二氮䓬类用量显著高于单药组(660 mg vs 340 mg,p<0.0001),提示联合组病情可能更重。
- 校正后联合组戒断缓解时间显著短于单药组(141.65 h vs 165.72 h,p<0.0001)。
- 联合组机械通气(19.42% vs 0.96%,p<0.0001)和吸入性肺炎(22.33% vs 5.77%,p=0.0006)发生率均显著高于单药组。
- 联合组住院时间显著长于单药组(8天 vs 6天,p=0.0197)。
- 联合组中24小时内启用苯巴比妥者苯二氮䓬类累积剂量更低(530 mg vs 887.50 mg,p=0.002)、住院时间更短(6天 vs 10天,p=0.0017)。
适用人群与场景
- 因酒精戒断综合征入院并接受苯巴比妥联合苯二氮䓬类治疗或苯二氮䓬类单药治疗的患者。
研究设计与关键结果
- 多中心回顾性队列研究,比较因酒精戒断综合征入院后接受苯巴比妥联合苯二氮䓬类治疗与苯二氮䓬类单药治疗的患者。
- 联合组苯二氮䓬类剂量显著高于单药组(660 mg vs 340 mg,p<0.0001)。
- 校正后联合组戒断缓解时间显著短于单药组(141.65 h vs 165.72 h,p<0.0001)。
- 联合组机械通气发生率19.42% vs 单药组0.96%(p<0.0001)。
- 联合组吸入性肺炎发生率22.33% vs 单药组5.77%(p=0.0006)。
- 联合组住院时间8天 vs 单药组6天(p=0.0197)。
- 联合组中24小时内启用苯巴比妥者苯二氮䓬类累积剂量530 mg vs 晚启用者887.50 mg(p=0.002),住院时间6天 vs 10天(p=0.0017)。
证据类型、等级与局限
- 证据类型:多中心回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,对重度酒精戒断高危患者,早期启用苯巴比妥似乎获益最大。
- 联合组机械通气、吸入性肺炎和住院时间增加,临床联用苯巴比妥时需关注这些风险。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND AND OBJECTIVE: Alcohol withdrawal syndrome (AWS) is a serious complication of alcohol use disorder. Although benzodiazepines are the mainstay of treatment, some patients may be resistant to them, requiring rapidly escalating doses. Phenobarbital has emerged as an effective adjunct therapy in severe alcohol withdrawal, but studies have yielded inconsistent results and carry safety risks. The purpose of our study was to examine the effectiveness and the potential harm of phenobarbital in AWS.
METHODS: In this multi-center, retrospective cohort study, patients who were admitted for AWS and received phenobarbital with benzodiazepine were compared to patients who received benzodiazepine monotherapy. The primary outcome was time to AWS resolution. Other secondary and safety outcomes included length of stay (LOS), rate of mechanical ventilation, and incidence of aspiration pneumonia.
RESULTS: The phenobarbital group received significantly higher doses of benzodiazepines compared to the benzodiazepine monotherapy group (660 mg vs 340 mg, p < 0.0001). After adjustment, the use of phenobarbital was associated with significantly reduced time to AWS resolution (141.65 h vs 165.72 h, p < 0.0001). However, the use of phenobarbital was associated with the likelihood of mechanical ventilation (19.42 %vs. 0.96 %, p < 0.0001), aspiration pneumonia (22.33 % vs 5.77 %, p = 0.0006), and increased hospital LOS (8 days vs. 6 days, p = 0.0197). In the combination group, earlier phenobarbital initiation (within 24 h) was associated with significantly lower cumulative benzodiazepine dose (530 mg vs 887.50 mg, p = 0.002) and hospital LOS (6 days vs 10 days, p = 0.0017).
CONCLUSION AND RELEVANCE: In our study, patients who received phenobarbital in combination with benzodiazepines had a quicker resolution of AWS but also had a higher incidence of mechanical ventilation, prolonged hospital LOS, and an increased risk of aspiration pneumonia. For patients at high risk of severe alcohol withdrawal, earlier initiation of phenobarbital appeared to yield the most optimal benefit.
参考来源
- Cheng XJC, Chung J, Yoo N, et al. Impact of phenobarbital when used in combination with benzodiazepines for the treatment of alcohol withdrawal syndrome: A retrospective analysis. Am J Emerg Med. 2025. PMID: 40080990. doi:10.1016/j.ajem.2025.03.008
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。